Home / Research Library / Betta Pharmaceuticals Co., Ltd Received a Patent for Icotinib
GIPResearch.com · Patent and Technology Research
Betta Pharmaceuticals Co., Ltd Received a Patent for Icotinib
Betta Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the research and development, manufacturing, sales and marketing of drugs to treat malignant tumors, diabetes, cardiovascular and cerebrovascular diseases. The Company’s core product is icotinib, which is a kind of…
Betta Pharmaceuticals Co., Ltd Received a Patent for Icotinib — research background
Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.
Betta Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the research and development, manufacturing, sales and marketing of drugs to treat malignant tumors, diabetes, cardiovascular and cerebrovascular diseases. The Company’s core product is icotinib, which is a kind of antineoplastic agent. Its products also include burn pain relieving plaster, oryzanol vitamin B1 and vitamin B6 tablets. The Company mainly operates its business in domestic market.
Betta Pharmaceuticals Co., Ltd filed patent application numbered 842/MUMNP/2014 that is titled METHODS OF PREPARING ICOTINIB AND ICOTINIB HYDROCHLORIDE AND INTERMEDIATES THEREOF. This patent application has been granted as Patent Number 311673.The invention covers chemical compounds. The present invention relates to the technical field of medicine. Provided are methods of preparing Icotinib, icotinib hydrochloride and intermediates thereof. The methods avoid the use of phosphoryl chloride thereby greatly reducing the emission of pollutants which is of major benefit to the economy and environment.During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that Claims 1- 6 are not patentable u/s 3(d) of the Patents Act, 1970 unless they differ significantly with regard to efficacy compared to known compound.As a response, the applicant submitted by explaining The process and the technical characteristics of the component to bring the uniqueness.Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
Discuss a research question related to Betta Pharmaceuticals Co., Ltd Received a Patent
Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.
Source and context: Original GIPResearch.com publication dated 2019-08-29. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.